Sequana Medical NV [SEQUA] vs Fagron NV [FAGR] Detailed Stock Comparison

Sequana Medical NV

EURONEXT
Loading...

Fagron NV

EURONEXT
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Sequana Medical NV wins in 4 metrics, Fagron NV wins in 11 metrics, with 0 ties. Fagron NV appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Sequana Medical NV Fagron NV Better
P/E Ratio (TTM) -0.46 19.15 Fagron NV
Price-to-Book Ratio N/A 3.15 N/A
Debt-to-Equity Ratio -1.06 84.34 Fagron NV
PEG Ratio -4.61 N/A N/A
EV/EBITDA -3.72 12.20 Fagron NV
Profit Margin (TTM) 74.94% 9.56% Sequana Medical NV
Operating Margin (TTM) -39,561.36% 15.08% Fagron NV
EBITDA Margin (TTM) N/A 15.08% N/A
Return on Equity 100.62% 17.24% Sequana Medical NV
Return on Assets (TTM) -88.40% 7.79% Fagron NV
Free Cash Flow (TTM) $-20.35M $124.64M Fagron NV
Dividend Yield N/A 1.60% N/A
1-Year Return 24.49% 11.32% Sequana Medical NV
Price-to-Sales Ratio (TTM) 384.56 1.83 Fagron NV
Enterprise Value $63.95M $2.04B Fagron NV
EV/Revenue Ratio 606.17 2.14 Fagron NV
Gross Profit Margin (TTM) 84.98% N/A N/A
Revenue per Share (TTM) $0 $13 Fagron NV
Earnings per Share (Diluted) $-1.23 $1.24 Fagron NV
Beta (Stock Volatility) -0.44 0.33 Sequana Medical NV

Sequana Medical NV vs Fagron NV Stock Performance Analysis

Loading Price Chart...

SEQUA
FAGR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Sequana Medical NV0.00%0.00%0.00%29.79%29.79%29.79%
Fagron NV0.86%-7.01%-3.73%2.88%10.74%6.67%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Sequana Medical NV24.49%24.49%24.49%24.49%24.49%24.49%
Fagron NV11.32%43.28%26.71%225.68%88.43%88.43%

Performance & Financial Health Analysis: Sequana Medical NV vs Fagron NV

MetricSEQUAFAGR
Market Information
Market Cap i€40.57M€1.73B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i160,626143,768
90 Day Avg. Volume i200,319126,387
Last Close€0.61€23.40
52 Week Range€0.46 - €1.62€19.24 - €25.30
% from 52W High-62.24%-7.51%
All-Time High€12.40 (Jan 04, 2021)€41.80 (Aug 04, 2014)
% from All-Time High-95.08%-44.02%
Growth Metrics
Quarterly Revenue Growth0.43%0.08%
Quarterly Earnings GrowthN/A0.13%
Financial Health
Profit Margin (TTM) i0.75%0.10%
Operating Margin (TTM) i-395.61%0.15%
Return on Equity (TTM) i1.01%0.17%
Debt to Equity (MRQ) i-1.0684.34
Cash & Liquidity
Book Value per Share (MRQ)€-0.69€7.53
Cash per Share (MRQ)€0.13€2.53
Operating Cash Flow (TTM) i€-17,625,734€155.26M
Levered Free Cash Flow (TTM) i€-13,009,764€83.53M
Dividends
Last 12-Month Dividend Yield iN/A1.60%
Last 12-Month Dividend iN/A€0.35

Valuation & Enterprise Metrics Analysis: Sequana Medical NV vs Fagron NV

MetricSEQUA (Apr 24, 2026)FAGR (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-0.4619.15
Forward P/E i-4.6114.43
PEG Ratio i-4.61N/A
Price to Sales (TTM) i384.561.83
Price to Book (MRQ) iN/A3.15
Market Capitalization
Market Capitalization i€40.57M€1.73B
Enterprise Value i€63.95M€2.04B
Enterprise Value Metrics
Enterprise to Revenue i606.172.14
Enterprise to EBITDA i-3.7212.20
Risk & Other Metrics
Beta i-0.440.33
Book Value per Share (MRQ) i€-0.69€7.53

Financial Statements Comparison: Sequana Medical NV vs Fagron NV

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSEQUA (2024)FAGR (2025)
Revenue/Sales i105,500952.17M
Cost of Goods Sold i26,443520.16M
COGS % of Revenue i25.1%54.6%
Gross Profit i79,057432.01M
Gross Margin i74.9%45.4%
Research & Development iN/AN/A
Operating Income (EBIT) i-18.22M147.45M
Operating Margin i-17,273.0%15.5%
EBITDA i-41.12M182.61M
EBITDA Margin i-38,978.3%19.2%
Pre-Tax Income i-44.37M117.59M
Pre-Tax Income % of Revenue i-42,059.9%12.4%
Income Tax i280,38326.07M
Income Tax % of Revenue i265.8%2.7%
Net Income (Profit) i-44.65M91.52M
Profit Margin i-42,325.7%9.6%

Balance Sheet & Liquidity Metrics

MetricSEQUA (2024)FAGR (2025)
Cash & Equivalents i3.81M184.90M
Total Current Assets i6.42M462.84M
Total Current Assets % of Revenue i6,082.2%48.6%
Total Current Liabilities i53.21M218.98M
Total Current Liabilities % of Revenue i50,436.9%23.0%
Long-Term Debt i357,902456.62M
Long-Term Debt % of Revenue i339.2%48.0%
Total Shareholders Equity i-44.38M556.26M
Retained Earnings i-250.68M330.75M
Retained Earnings % of Revenue i-237,607.2%34.7%
Property, Plant & Equipment i1.28M219.59M

Cash Flow Statement Comparison

MetricSEQUA (2024)FAGR (2025)
Operating Cash Flow i-17.83M135.71M
Operating Cash Flow % of Revenue i-16,898.2%14.3%
Capital Expenditures i-95,130-15.36M
Free Cash Flow i-20.35M124.64M
FCF Margin i-19,292.2%13.1%
Debt Repayment i-157,741-89.41M
Common Stock Repurchase iN/A-4.14M

Short Interest & Institutional Ownership Analysis

MetricSEQUAFAGR
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i57.21M73.24M
Float Shares i34.99M65.76M
% Held by Insiders i13.26%0.30%
% Held by Institutions i29.15%67.28%
% Held by Public i57.59%32.42%

Dividend Analysis & Yield Comparison: Sequana Medical NV vs Fagron NV

MetricSEQUAFAGR
Last 12-Month Dividend iN/A€0.35
Last 12-Month Dividend Yield iN/A1.60%
3-Year Avg Annual Dividend iN/A€0.30
3-Year Avg Dividend Yield iN/A1.58%
3-Year Total Dividends iN/A€0.90
Ex-Dividend DateN/AMay 19, 2025